Your browser is no longer supported. Please, upgrade your browser.
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own2.30% Shs Outstand342.73M Perf Week-1.00%
Market Cap7.49B Forward P/E2.84 EPS next Y7.70 Insider Trans2.74% Shs Float332.43M Perf Month-16.89%
Income-988.40M PEG- EPS next Q1.76 Inst Own66.80% Short Float8.29% Perf Quarter-5.58%
Sales10.32B P/S0.73 EPS this Y-133.00% Inst Trans20.57% Short Ratio1.32 Perf Half Y-38.04%
Book/sh15.35 P/B1.42 EPS next Y18.53% ROA-2.00% Target Price43.53 Perf Year-80.06%
Cash/sh2.49 P/C8.78 EPS next 5Y11.07% ROE-17.00% 52W Range18.55 - 127.08 Perf YTD-78.51%
Dividend- P/FCF5.75 EPS past 5Y4.40% ROI3.70% 52W High-82.48% Beta-0.23
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin74.70% 52W Low20.00% ATR0.88
Employees22000 Current Ratio1.40 Sales Q/Q-50.60% Oper. Margin7.70% RSI (14)36.65 Volatility3.06% 3.88%
OptionableYes Debt/Eq5.87 EPS Q/Q-780.40% Profit Margin-9.60% Rel Volume0.37 Prev Close21.84
ShortableYes LT Debt/Eq5.81 EarningsNov 08 BMO Payout- Avg Volume20.80M Price22.26
Recom2.90 SMA20-2.88% SMA50-15.56% SMA200-42.37% Volume5,720,892 Change1.92%
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Oct-27-16 11:45AM  The woman behind 'female Viagra' sold her company for $1 billion that's when everything fell apart
09:30AM  Is Valeant Pharmaceuticals Now a Drug-Pricing Role Model? at Motley Fool
02:04AM  Pharming Reports on Financial Results for the First Nine Months of 2016 PR Newswire
Oct-26-16 06:04PM  Bill Miller Says Valeant Pharmaceuticals Could Double in 3 Years
04:58PM  Bill Miller: Valeant Can Double in 3 Years
11:15AM  Is This MannKind's Last Remaining Option? at Motley Fool
09:51AM  Investors Have Yanked $60 Billion From Hedge Funds This Year at Forbes
Oct-25-16 03:40PM  Citron's Andrew Left Likes Amazon, Says He's Long
03:11PM  A Month Later, the For Sale Sign Still Sits in iNova's Front Yard, Much to Valeant's Dismay at Motley Fool
09:18AM  Heres Why Tesla Motors Inc (TSLA), Netflix, Inc. (NFLX), and Three Other Stocks Are in Spotlight at Insider Monkey
Oct-24-16 03:22PM  Valeant Pharmaceuticals: Bill Miller Isn't Following JPMorgan's Advice at
02:16PM  Valeant (VRX) Stock Down, JPMorgan: Avoid Before Q3 Results
01:52PM  Valeant Pharmaceuticals (VRX) Stock Could Double in Three Years, LMM CIO Bill Miller Says
01:09PM  Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says at
Oct-21-16 08:00AM  Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
Oct-20-16 04:51PM  Headline Risk Is Still Poison for These Stocks
09:00AM  Headline Risk Is Still Poison For These Stocks
09:00AM  BMRA: Base Business Bounces Back, InFoods Continues To Attract Whos-Who of IBS
Oct-19-16 03:58PM  Jim Chanos uses this 7-point checklist for companies he's going to short
Oct-18-16 03:00PM  Stock Picking Is Not Dead
01:04PM  Vertex Not the Only Pharmaceutical to See Its Share Price Fall
10:37AM  Another shady business relationship has Wall Street worried about Valeant
10:05AM  How Valeant Is Expected to Pay down Its Debt
08:05AM  Valeants Investment Here Could Improve Future Profit Margins
Oct-17-16 06:15PM  Pharma Stocks Prone to Decline From Democratic Win (MYL, ARIA) at Investopedia
05:57PM  Valeant Cuts Ties With Pharmacy That Distributed Antidepressant at Bloomberg
05:04PM  Valeant Counts on Baush + Lomb for Revenue Growth
03:50PM  3 Things Valeant Pharmaceuticals Needs to Do to Win Over Wall Street at Motley Fool
03:04PM  Valeants Reorganization Efforts Could Boost Investor Confidence
01:17PM  Valeant Looks to Line Its Coffers Using These Five Strategies
12:20PM  Valeant Announces Third Quarter Financial Results Date And Conference Call Details PR Newswire
12:20PM  Valeant Announces Third Quarter Financial Results Date And Conference Call Details CNW Group
09:15AM  Blog Coverage Valeant Pharma Announces Moderate Increase in Prices of its Neurology, Gastrointestinal and Urology Drugs Accesswire
09:12AM  Blog Coverage Valeant Pharma Announces Moderate Increase in Prices of its Neurology, Gastrointestinal and Urology Drugs
08:04AM  This Space Presents a Market Opportunity for Valeant
07:00AM  5 Things You Must Know Before the Market Opens Monday
Oct-16-16 11:16AM  Why Biotech Investors Are Terrified of the Upcoming Elections at Motley Fool
Oct-15-16 12:34PM  Heres Why These Five Stocks Are in the Spotlight at Insider Monkey
Oct-14-16 11:06PM  [$$] Valeant Sets Price Increases for Some Drugs at The Wall Street Journal
06:49PM  Gimme Credit: Valeant May Fall Short of Guidance Again at
04:28PM  [$$] Valeant Sets Price Increases for Some Drugs at The Wall Street Journal
04:08PM  Here's Why Valeant Pharmaceuticals (VRX) Stock Closed Lower Today
03:09PM  Valeant Pharmaceuticals: And You Thought They Changed at
02:30PM  Valeant announces price increases of 2% to 9% for neurology, gastrointestinal disorder and urology portfolios at MarketWatch
02:15PM  Stressed Out: Free Cash Flow Is All That Counts Now for Valeant
01:49PM  Valeant Releases Drug Price Information Ahead of Earnings
01:33PM  Valeant raises list prices of some products by up to 9 pct Reuters
01:20PM  Ruane Cunniff Makes One Significant Buy
12:51PM  Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions PR Newswire
12:51PM  Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions CNW Group
12:22PM  3 Candidates for Worst CEO of 2016 at Motley Fool
11:04AM  How Valeant Is Trying to Improve Its Profit Margins
10:04AM  Valeant Looks to Boost Profit Margins through the Walgreens Deal
08:30AM  Valeant Is Poised to Disappoint at Bloomberg
08:04AM  Strong Tailwinds Expected to Boost Valeants Earnings This Year
Oct-13-16 05:04PM  Valeant Thinks It Will Hit Its Financial Targets in 2016
04:04PM  Valeant Could Move Higher If This Strategy Is Successful
01:53PM  Valuation Multiples: How Valeant Compares to Its Peers
Oct-12-16 06:09PM  The Pharmaceutical Sector Looks Attractive
03:46PM  This Bernie Sanders tweet about Flint's water crisis could be a big problem for Valeant
11:53AM  This is the earnings metric stock-market investors should focus on at MarketWatch
Oct-11-16 10:00AM  Stay Away From These 5 Stocks This Earnings Season
Oct-09-16 03:30PM  Mindset Shifts Take Time
02:28PM  Don't Blame Mylan's CEO for EpiPen's Soaring Price, Blame the U.S. Healthcare System at Motley Fool
Oct-07-16 12:56PM  These 2 Factors Pushed Valeant Pharmaceuticals Intl. Inc. Down 15% in September at Motley Fool
Oct-06-16 04:20PM  Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer PR Newswire
04:20PM  Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer CNW Group
03:02PM  Specialty Pharma: Drug Pricing Controversies Just Won't Die! at
Oct-05-16 02:41PM  Ariad Pharmaceuticals Raises Cancer Drug Price For The 4th Time This Year
12:30PM  Pharming Reports on Extraordinary General Meeting of Shareholders PR Newswire
Oct-04-16 12:18PM  Why Progenics Pharmaceuticals, Inc. Is Rising Today at Motley Fool
08:27AM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
Oct-03-16 11:09PM  AP Top Extended Financial Headlines at 11:09 p.m. EDT
04:51PM  Hedge Funds Must Regret Having Sold Off These 5 Stocks: from Apple Inc. (AAPL) to Valeant Pharmaceuticals Inc. (VRX) at Insider Monkey
02:17PM  Valeants Stock Becomes (Relatively) Quiet After Wild Year at Bloomberg
11:31AM  The Street Is Underestimating Valeant's Potential Downside From Legal Woes
09:05AM  Dont Get Caught With These 5 Stocks Ahead of Earnings Season
01:00AM  Pharming Reports on Financial Results for the First Eight Months of 2016 PR Newswire
Oct-02-16 12:44PM  Passing Inflection Point on Pricing and Profits
Sep-30-16 02:04PM  What Are Analysts Saying about Mallinckrodt?
01:58PM  How Valeants Scandal Has Impacted Its Stock Price (VRX) at Investopedia
08:05AM  Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc at Motley Fool
Sep-29-16 04:50PM  CANADA STOCKS-TSX rises to 1-week high as energy adds to OPEC-related gains -5.19%
03:22PM  No Matter Who Becomes President, Valeant Pharmaceuticals Could Lose Pricing Power at Motley Fool
11:20AM  Valeant Pharmaceuticals: At Least They Have a Sense of Humor at
Sep-28-16 03:49PM  Short seller report sends shares of LaCroix-maker down 11% at CNBC
10:40AM  Valeant Pharmaceuticals International, Inc. Value Analysis (NYSE:VRX) : September 28, 2016
Sep-27-16 02:01PM  Drug Price Bubble A Result Of Decade-Long Economic Policy Issues
01:07PM  Revisiting Three Market Villains (CMG, VRX) at Investopedia
11:55AM  Here's Why You Shouldn't Pay Much Attention to Wall Street Analysts' Stock Ratings at Motley Fool
08:33AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : VRX-US : September 27, 2016
Sep-26-16 03:42PM  Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says -6.60%
02:46PM  Who's Doing What To Whom In The Back Seat Of The Car? at Forbes
02:09PM  Trending Tickers: TWTR, VRX, ENDP, RIG
01:30PM  Andrew Left Says Trump and Clinton Agree on Just One Thing
08:25AM  Can You Guess Which Big Pharma Has Raised Its Drug Prices 5 Times Since June 2014? at Motley Fool
Sep-25-16 01:04PM  Dont fire until you see the whites of their eyes
10:00AM  Wealth Preservation: "All I Know Is That I Know Nothing" at Investopedia
Sep-23-16 05:25PM  Investing for the Next 100 Years at
04:46PM  Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM